Summary of retrospective and prospective studies for cHL in older patients
| . | N . | Period . | Age (range), y . | Advanced stage . | Treatment . | CR rate . | Toxic death . | Infectious toxicities∗ . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Retrospective studies | ||||||||||
| Evens et al4 | 95† | 1999-2009 | 67 60-89 | 64% | ABVD | 75% | 6% | — | 44% at 5 y | 58% at 5 y |
| Stamatoullas et al5 | 147 | 1997-2012 | 68 60-88 | 57% | ABVD | 80% | 10% | — | — | 67% at 5 y |
| Orellana-Noia et al30 | 190‡ | 2010-2018 | 67 60-88 | 64% | ABVD, AVD, BV+AVD, Stanford V | — | 3.3% | — | 67% at 3 y | 87% at 3 y |
| Wahlin et al40 | 691 | 2000-2014 | —61-99 | 51% | ABVD CHOP | — | — | — | — | 75% at 5 y ≈40% at 5 y |
| Cheng et al31 | 401 | 2000-2019 | 70 60-93 | 72% | ABVD, AVD, BV+AVD, Others | — | 5% | — | 50% at 5 y | 54% at 5 y |
| Övergaard et al32 | 1554 | 2000-2021 | 70 60-94 | — | ABVD AVD CHOP Other | 63% at 5 y 64% at 5 y 46% at 5 y 39% at 5 y | ||||
| Prospective studies | ||||||||||
| Böll et al6 | 59 | 2004-2007 | 68 60-75 | 100% | PVAG | 78% | 2% | G3/4 infections: 23% | 58% at 3 y | 66% at 3 y |
| Proctor et al7 | 103 | 2004-2009 | 73 61-85 | 70% | VEPEMB | 65% | 3% | FN: 16% G3/4 infections: 3% | 53% at 3 y | 62% at 3 y |
| Evens et al19 | 45 | 1999-2006 | 65 60-83 | 93% | ABVD vs Stanford V | 64% | 9% | FN: 8% FN: 15% | 48% at 5 y | 58% at 5 y |
| Böll et al29 | 49 | 2015-2017 | 66 60-84 | 100% | BV-CAP | 65%§ | 2% | FN: 27% G3/4 infections: 33% | 74% at 1 y | 92% at 1 y |
| Evens et al23 | 48 | 2012-2016 | 69 60-88 | 81% | BV × 2 AVD × 6 BV × 4 | 93%§ | 2% | FN: 8% | 84% at 2 y | 93% at 2 y |
| Evens et al28 | 186 | 2012-2016 | 67 60-83 | 100% | ABVD vs BV-AVD | 71%§, 74%§ | 4.4% | FN: 17% FN: 37% | 67% at 5 y 62% at 5 y | — |
| Torka et al41 | 33 | — | Nivolumab AVD × 6 | 97%§ | 0% | FN: 8% | 86% at 2 y | 96% at 2 y | ||
| PVAB study | 89 | 2015-2018 | 68 61-88 | 100% | PVAB | 77%§ | 4% | FN: 7% G3/4 infections: 10% | 50% at 4 y | 69% at 4 y |
| . | N . | Period . | Age (range), y . | Advanced stage . | Treatment . | CR rate . | Toxic death . | Infectious toxicities∗ . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Retrospective studies | ||||||||||
| Evens et al4 | 95† | 1999-2009 | 67 60-89 | 64% | ABVD | 75% | 6% | — | 44% at 5 y | 58% at 5 y |
| Stamatoullas et al5 | 147 | 1997-2012 | 68 60-88 | 57% | ABVD | 80% | 10% | — | — | 67% at 5 y |
| Orellana-Noia et al30 | 190‡ | 2010-2018 | 67 60-88 | 64% | ABVD, AVD, BV+AVD, Stanford V | — | 3.3% | — | 67% at 3 y | 87% at 3 y |
| Wahlin et al40 | 691 | 2000-2014 | —61-99 | 51% | ABVD CHOP | — | — | — | — | 75% at 5 y ≈40% at 5 y |
| Cheng et al31 | 401 | 2000-2019 | 70 60-93 | 72% | ABVD, AVD, BV+AVD, Others | — | 5% | — | 50% at 5 y | 54% at 5 y |
| Övergaard et al32 | 1554 | 2000-2021 | 70 60-94 | — | ABVD AVD CHOP Other | 63% at 5 y 64% at 5 y 46% at 5 y 39% at 5 y | ||||
| Prospective studies | ||||||||||
| Böll et al6 | 59 | 2004-2007 | 68 60-75 | 100% | PVAG | 78% | 2% | G3/4 infections: 23% | 58% at 3 y | 66% at 3 y |
| Proctor et al7 | 103 | 2004-2009 | 73 61-85 | 70% | VEPEMB | 65% | 3% | FN: 16% G3/4 infections: 3% | 53% at 3 y | 62% at 3 y |
| Evens et al19 | 45 | 1999-2006 | 65 60-83 | 93% | ABVD vs Stanford V | 64% | 9% | FN: 8% FN: 15% | 48% at 5 y | 58% at 5 y |
| Böll et al29 | 49 | 2015-2017 | 66 60-84 | 100% | BV-CAP | 65%§ | 2% | FN: 27% G3/4 infections: 33% | 74% at 1 y | 92% at 1 y |
| Evens et al23 | 48 | 2012-2016 | 69 60-88 | 81% | BV × 2 AVD × 6 BV × 4 | 93%§ | 2% | FN: 8% | 84% at 2 y | 93% at 2 y |
| Evens et al28 | 186 | 2012-2016 | 67 60-83 | 100% | ABVD vs BV-AVD | 71%§, 74%§ | 4.4% | FN: 17% FN: 37% | 67% at 5 y 62% at 5 y | — |
| Torka et al41 | 33 | — | Nivolumab AVD × 6 | 97%§ | 0% | FN: 8% | 86% at 2 y | 96% at 2 y | ||
| PVAB study | 89 | 2015-2018 | 68 61-88 | 100% | PVAB | 77%§ | 4% | FN: 7% G3/4 infections: 10% | 50% at 4 y | 69% at 4 y |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; PVAG, prednisone, vinblastine, doxorubicin, and gemcitabine; VEPEMB, vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin; BV-CAP, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; FN, febrile neutropenia; G3/4, grade 3 or 4.
Documented for prospective studies.
67 patients treated with ABVD.
244 patients, including 190 patients treated with conventional therapies and 54 with alternative regimens.
Evaluation by PET/CT.